Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Committee hears bill to eliminate out‑of‑pocket costs for follow‑up cervical diagnostic tests
Summary
Senate Bill 451 would prohibit many commercial insurers from charging deductibles or co‑payments for medically necessary cervical cancer diagnostic follow‑ups after an abnormal screening. Physicians, clinician organizations and cancer advocates testified in support, describing the measure as a way to reduce delays and disparities in care.
Senate Committee on Health Care opened a public hearing on Senate Bill 451 on Feb. 25, 2025. The bill would prohibit certain health insurance carriers from imposing deductibles, coinsurance, co‑payments or other out‑of‑pocket expenses for medically necessary cervical cancer screenings and follow‑up diagnostic examinations when abnormalities are detected on initial screening.
Physicians and advocacy groups told the committee the change would reduce financial barriers that sometimes prevent timely diagnostic evaluation after an abnormal Pap test. Dr. Stella Dantes, a full‑time obstetrician‑gynecologist and national president of the…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
